Literature DB >> 29551705

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients.

Dirk Westhölter1, Jens Hiller2, Ulrike Denzer2, Susanne Polywka3, Francis Ayuk4, Meike Rybczynski5, Thomas Horvatits6, Svantje Gundlach7, Johanna Blöcker6, Julian Schulze Zur Wiesch8, Nicole Fischer9, Marylyn M Addo8, Sven Peine2, Burkhard Göke10, Ansgar W Lohse8, Marc Lütgehetmann9, Sven Pischke8.   

Abstract

BACKGROUND & AIMS: Routine HEV testing of blood products has recently been implemented in Great Britain and the Netherlands. The relevance of transfusion-transmitted HEV infections is still controversially discussed in Europe.
METHODS: All blood donations at the University Medical Center Hamburg-Eppendorf were prospectively tested for HEV RNA by pooled PCR from October 2016 to May 2017. Reactive samples were individually retested. Additionally, stored samples from previous donations of positive donors were tested to determine the duration of HEV viraemia. HEV RNA-positive donors and a control cohort were asked to answer a questionnaire.
RESULTS: Twenty-three out of 18,737 HEV RNA-positive donors were identified (0.12%). Only two of the positive donors (8.7%) presented with elevated aminotransferases at time of donation (alanine aminotransferase: 192 and 101 U/L). The retrospective analysis of all positive donors revealed that four asymptomatic donors had been HEV viraemic for up to three months with the longest duration of HEV viraemia exceeding four months. Despite the HEV-testing efforts, 14 HEV RNA-positive blood products were transfused into 12 immunocompromised and two immunocompetent patients. One recipient of these products developed fatal acute-on-chronic liver failure complicated by Pseudomonas septicemia. The questionnaire revealed that HEV RNA-positive donors significantly more often consumed raw pork meat (12 out of 18; 67%) than controls (89 out of 256; 35%; p = 0.01). In two donors, undercooked pork liver dishes were identified as the source of infection. HEV genotyping was possible in 7 out of 23 of HEV viraemic donors and six out of seven isolates belonged to HEV Genotype 3, Group 2.
CONCLUSIONS: Prolonged HEV viraemia can be detected at a relatively high rate in Northern German blood donors, leading to transfusion-transmitted HEV infections in several patients with the risk of severe and fatal complications. Eating raw pork tartare represented a relevant risk for the acquisition of HEV infection. LAY
SUMMARY: The relevance of transfusion-transmitted hepatitis E virus infections has been discussed controversially. Herein, we present the first report on routine hepatitis E virus screening of blood donations at a tertiary care centre in Germany. Hepatitis E viraemia was found at a relatively high rate of 0.12% among blood donors, which represents a relevant transfusion-related risk for vulnerable patient populations.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-borne hepatitis E virus infection; Hepatitis E virus; Hepatitis E virus blood donor screening; Transfusion-transmitted hepatitis E virus infection

Mesh:

Substances:

Year:  2018        PMID: 29551705     DOI: 10.1016/j.jhep.2018.02.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  [Viral hepatitis A-E].

Authors:  Annegrit Decker; Christoph Neumann-Haefelin; Robert Thimme
Journal:  Internist (Berl)       Date:  2021-02       Impact factor: 0.743

Review 2.  Blood Donor Screening for Hepatitis E Virus in the European Union.

Authors:  Fiona Boland; Auxiliadora Martinez; Louise Pomeroy; Niamh O'Flaherty
Journal:  Transfus Med Hemother       Date:  2019-03-14       Impact factor: 3.747

3.  HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party.

Authors:  Malgorzata Mikulska; Olaf Penack; Lotus Wendel; Nina Knelange; Jan J Cornelissen; Nicole Blijlevens; Jakob Passweg; Nicolaus Kroger; Anke Bruns; Christian Koenecke; Marc Bierings; José Luis Piñana; Helene Labussiere-Wallet; Herve Ghesquieres; Miguel Angel Diaz; Antonia Sampol; Diana Averbuch; Rafael de la Camara; Jan Styczynski
Journal:  Bone Marrow Transplant       Date:  2021-10-23       Impact factor: 5.483

4.  Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors.

Authors:  Gui-Ping Wen; Chang-Rong Chen; Xiu-Yu Song; Zi-Min Tang; Wen-Fang Ji; Si-Ling Wang; Ke Zhang; Jun Zhang; Shan-Hai Ou; Zi-Zheng Zheng; Ning-Shao Xia
Journal:  Emerg Microbes Infect       Date:  2018-07-05       Impact factor: 7.163

Review 5.  Hepatitis E virus (HEV)-The Future.

Authors:  Joachim Denner
Journal:  Viruses       Date:  2019-03-13       Impact factor: 5.048

6.  Why all blood donations should be tested for hepatitis E virus (HEV).

Authors:  Joachim Denner; Sven Pischke; Eike Steinmann; Johannes Blümel; Dieter Glebe
Journal:  BMC Infect Dis       Date:  2019-06-20       Impact factor: 3.090

Review 7.  The Clinical Perspective on Hepatitis E.

Authors:  Thomas Horvatits; Julian Schulze Zur Wiesch; Marc Lütgehetmann; Ansgar W Lohse; Sven Pischke
Journal:  Viruses       Date:  2019-07-05       Impact factor: 5.048

8.  The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis.

Authors:  Pengfei Li; Jiaye Liu; Yang Li; Junhong Su; Zhongren Ma; Wichor M Bramer; Wanlu Cao; Robert A de Man; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Liver Int       Date:  2020-04-24       Impact factor: 5.828

9.  Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E.

Authors:  Marten Schulz; Paula Biedermann; Claus-Thomas Bock; Jörg Hofmann; Mira Choi; Frank Tacke; Leif Gunnar Hanitsch; Tobias Mueller
Journal:  Int J Environ Res Public Health       Date:  2020-01-03       Impact factor: 3.390

10.  Hepatitis E virus prevalence among blood donors in Dali, China.

Authors:  Ping Fu; Baochai Lin; Bingting Wu; Ling Ke; Tianfu Yang; Yue'e Du; Lishan Cheng; Zhou Li; Tiancheng Li; Yu Liu
Journal:  Virol J       Date:  2021-07-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.